Hemophilia A players in the green on BioMarin gene therapy delay in U.S.

On script, BioMarin Pharmaceutical’s (BMRN -36.2%) stumble with hemophilia A gene therapy candidate valoctogene roxaparvovec has stoked modest buying in other players in the space as investors perceive improved prospects from the sidelining of a key competitor.

Earlier today, it announced that it received a CRL citing the need for more data to prove the duration of the treatment effect, extending the timeline for possible approval into 2022.

Selected tickers: Regeneron Pharmaceuticals (REGN +3.2%), Intellia Therapeutics (NTLA +1.9%), Bayer (OTCPK:BAYRYBAYRY 17.16 0.13 0.76% Bayer Aktiengesellschaft Bayer Aktiengesellschaft operates as a life science company worldwide. More » (10,508 followers) +0.6%), Sangamo Therapeutics (SGMO +2.8%), Novo Nordisk (NVO +0.7%), Catalyst Biosciences (CBIO +0.6%), Roche (OTCQX:RHHBY +1.1%)

https://seekingalpha.com/news/3607153-hemophilia-players-in-green-on-biomarin-gene-therapy-delay-in-u-s